SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-18-001003
Filing Date
2018-05-15
Accepted
2018-05-15 17:23:12
Documents
39
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymx_6k.htm 6-K 8310
2 QUARTERLY REPORT FOR THE QUARTER ENDED nymx_ex991.htm EX-99.1 174775
3 CEO CERTIFICATION nymx_ex992.htm EX-99.2 8786
4 CFO CERTIFICATION nymx_ex993.htm EX-99.3 8395
11 nymox_ex991img3.jpg GRAPHIC 4843
  Complete submission text file 0001640334-18-001003.txt   1260977

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT nymx-20180331.xml EX-101.INS 195422
6 XBRL TAXONOMY EXTENSION SCHEMA nymx-20180331.xsd EX-101.SCH 39659
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20180331_cal.xml EX-101.CAL 24819
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20180331_def.xml EX-101.DEF 39614
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20180331_lab.xml EX-101.LAB 122311
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20180331_pre.xml EX-101.PRE 93235
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 18837880
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Assistant Director 1